Abstract
To the Editor: In the article by Van Vliet et al. (Oct. 27 issue) the effects of human growth hormone treatment are reported in short normal children.1 Growth hormone doses were comparable to those used for therapy in hypopituitarism. The authors point out that the prospects for children with stunted growth will change dramatically, since there will be no theoretical limit to the amount of biosynthetic human growth hormone produced by recombinant-DNA technology.1 Recently, we studied the response to growth hormone treatment in prenatal dwarfism and Turner's syndrome.One patient with the Silver–Russell syndrome received growth hormone therapy for more . . .